A phase 2, randomized, active comparator-controlled, dose-ranging study to evaluate the efficacy and safety of TAK-442 in subjects undergoing total knee replacement.

Trial Profile

A phase 2, randomized, active comparator-controlled, dose-ranging study to evaluate the efficacy and safety of TAK-442 in subjects undergoing total knee replacement.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Enoxaparin sodium; Letaxaban
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 05 Dec 2009 Results have been presented at the 51st Annual Meeting and Exposition of the American Society of Hematology.
    • 19 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 19 Dec 2008 Planned number of patients changed from 1050 to 1045 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top